European Research Revolution: Key Takeaways for Pharma
Decision brief
Answer first · skim in under a minute
The European Research Revolution advances pharmaceutical innovation through translational research models and EU funding mechanisms, emphasizing cross-border collaboration and precision medicine initiatives across member states.
Key questions this brief answers
- How much does Europe invest in pharmaceutical R&D annually?
- What is EMA accelerated assessment and how fast is it?
- How many clinical trials are active in the EU?
- What EU funding programs support pharmaceutical research?
- How is Europe performing in new drug development versus the US and China?
European pharmaceutical research commands €60 billion in annual R&D investment and drives cross-border collaboration through programs like Horizon Europe and the Innovative Health Initiative. The European Medicines Agency (EMA) accelerated assessment pathway now delivers marketing-authorisation decisions in 150 days—60 days faster than standard review—while the Clinical Trials Information System (CTIS) tracks over 6,400 active trials across the EU.
Contents11 sections
Key Takeaways
- Europe invested €60 billion in pharmaceutical R&D in 2025, representing 23.7% of global pharmaceutical sales, trailing North America at 54.7% according to EFPIA data.
- EMA accelerated assessment cuts review time by 60 days, reducing the standard 210-day timeframe to 150 days for medicines demonstrating therapeutic innovation and major public health interest.
- CTIS recorded 13,778 clinical trial applications since launch, with 6,425 trials currently active in the EU/EEA under the Clinical Trials Regulation as of March 2026.
- The Innovative Health Initiative operates a €2.4 billion budget through 2027, with IHI Joint Undertaking commitments totaling €1.45 billion of the €1.60 billion maximum Union contribution.
- Europe trails China in new active substance launches—16 versus 46 from China and 28 from the US in 2025—prompting calls for increased investment to close the gap.
How Much Does Europe Invest in Pharmaceutical R&D?
The European pharmaceutical industry directed an estimated €60 billion into R&D in 2025. This figure positions Europe as the second-largest regional investor, though it faces mounting competitive pressure. North America captured 54.7% of estimated world pharmaceutical sales in 2025, while Europe held 23.7%.
China now outpaces both regions in originating new active substances (NAS). Chinese companies launched 46 new molecules globally in 2025, compared to 28 from US firms and 16 from European sponsors. EFPIA analysis suggests closing this innovation gap would require the EU to attract substantially more investment—potentially yielding an additional €105 billion over a 10-year period by 2035.
What Is EMA Accelerated Assessment?
The EMA accelerated assessment pathway reduces marketing-authorisation review from 210 days to 150 days. This 60-day reduction applies to products demonstrating both major public health interest and therapeutic innovation.
Sponsors may request accelerated assessment 2-3 months before submission. The EMA recommends pre-submission meetings to discuss eligibility criteria and review timelines. The pathway integrates with the PRIME (Priority Medicines) scheme, which provides enhanced development support including early scientific advice.
The EMA's Regulatory Science Strategy to 2025 underpins these acceleration efforts. The strategy aims to advance regulatory science, integrate new technologies, and improve patient access to innovative medicines through coordinated scientific advice and parallel regulatory pathways.
How Many Clinical Trials Are Active in the EU?
Clinical trial activity in Europe operates at significant scale. The Clinical Trials Information System (CTIS) has received 13,778 applications since its launch. As of March 2026, 6,425 initial clinical trials remained active across the EU/EEA under the Clinical Trials Regulation (EU) No 536/2014.
Neoplasms (tumors) rank as the most commonly investigated therapeutic area. Advanced Therapy Medicinal Products (ATMPs)—including gene and cell therapies—account for 486 authorized trials, with 21 new ATMP trials authorized in Q1 2026 alone.
Recruitment timelines show room for improvement. Currently, 40.5% of clinical trials recruit participants within 200 days of application submission. The EU target calls for 66% recruitment within this window by 2030. An additional 500 multinational clinical trials are targeted for authorization by 2030 above historical averages.
What EU Funding Programs Support Drug Development?
Horizon Europe serves as the primary EU framework for pharmaceutical research funding. The 2026 Health calls opened February 10, 2026, with deadlines of April 16, 2026. Relevant topics include:
| Call Identifier | Focus Area | Budget Context |
|---|---|---|
| HORIZON-HLTH-2026-01-DISEASE-04 | Novel vaccines for viral pathogens with epidemic potential | Horizon Europe Health Cluster |
| HORIZON-HLTH-2026-01-TOOL-03 | Integrating New Approach Methodologies (NAMs) for regulatory testing | Tools and technologies |
| HORIZON-HLTH-2026-01-IND-03 | Regulatory science for patient-centred health technologies | Industry and translation |
| HORIZON-HLTH-2026-01-TOOL-05 | Regenerative medicine follow-on funding pilots | Advanced therapies |
The European Joint Programme on Rare Diseases (EJP RD) has funded 77 multinational projects with €104.7 million across 35 countries and 130 institutions. The program involved 24 European Reference Networks (ERNs) and trained nearly 1,500 researchers, clinicians, and patients.
How Do Cross-Border Collaborations Work?
European pharmaceutical innovation depends on structured frameworks linking academic centers, biotech companies, and established pharmaceutical sponsors. These partnerships enable resource sharing, reduce redundant research, and accelerate translation from discovery to therapeutic candidates.
The Innovative Health Initiative (IHI) Joint Undertaking—successor to IMI2—operates with a €2.4 billion budget through 2027. Half derives from Horizon Europe; half from industry contributions. The program has generated 275 assets including tools, methodologies, and processes—exceeding its target of 50.
Successful collaboration models include:
- Academic-industry consortia targeting specific therapeutic areas or disease mechanisms
- Cross-border networks using complementary expertise across member states
- Public funding mechanisms that de-risk early-stage research for private investment
- Shared research infrastructure and biobanking resources accessible to multiple organizations
What Challenges Does European Pharma Research Face?
Several structural challenges constrain European competitiveness. Increasing regulatory complexity, escalating R&D costs, and fiscal austerity measures introduced since 2010 have tightened investment conditions. Economic activity shows gradual migration toward emerging markets—Brazil, China, and India—where growth rates outpace Europe.
The new active substance launch gap illustrates the competitive pressure. With only 16 European-originated NAS launches versus 46 from China, European sponsors risk losing ground in novel therapeutic development. EFPIA estimates suggest recovering this position requires substantial policy support and funding alignment.
Clinical trial recruitment efficiency also presents challenges. At 40.5% recruitment within 200 days, the EU trails the 66% target set for 2030. Sponsors and sites must streamline patient identification and enrollment processes to meet these goals.
What Developments Should Investors Monitor?
Key indicators for European pharmaceutical research progress include:
- EU funding program allocations for fiscal year 2026-2027, particularly Horizon Europe Health cluster disbursements
- EMA regulatory guidance updates on accelerated pathways and novel therapeutic modalities
- Publication of research findings from major consortia and their translation into clinical programs
- Industry partnerships and licensing agreements from European academic institutions
- Clinical trial initiation announcements from European biotech and pharmaceutical sponsors
The EMEA 2026 Life Sciences Report provides additional regional context for strategic planning. For regulatory developments, see our EC nod for Chiesi Lojuxta analysis. The pharma packaging market report covers drug delivery innovations.
Frequently Asked Questions
How much does Europe invest in pharmaceutical R&D annually?
The European pharmaceutical industry invested an estimated €60 billion in R&D in 2025 according to EFPIA data. This places Europe second globally, with North America accounting for 54.7% of world pharmaceutical sales and Europe at 23.7%.
What is EMA accelerated assessment and how fast is it?
EMA accelerated assessment reduces the standard marketing-authorisation review timeframe from 210 days to 150 days for products demonstrating major public health interest and therapeutic innovation. Applicants may request this process 2-3 months before submission.
How many clinical trials are active in the EU?
As of March 2026, the Clinical Trials Information System (CTIS) recorded 13,778 clinical trial applications submitted since launch, with 6,425 initial clinical trials ongoing in the EU/EEA under the Clinical Trials Regulation.
What EU funding programs support pharmaceutical research?
Horizon Europe provides primary funding through calls like HORIZON-HLTH-2026-01 for drug development, novel vaccines, and regulatory science. The Innovative Health Initiative (IHI) operates with a €2.4 billion budget through 2027. The European Joint Programme on Rare Diseases (EJP RD) funded 77 multinational projects with €104.7 million across 35 countries.
How is Europe performing in new drug development versus the US and China?
In 2025, China originated 46 new active substances (NAS) launched globally, compared to 28 from the US and 16 from Europe. EFPIA projects that closing this gap could yield an additional €105 billion in R&D investment over 10 years by 2035.
Primary Sources
- European Medicines Agency. "Accelerated Assessment." ema.europa.eu. Accessed July 2026.
- European Medicines Agency. "Regulatory Science Strategy to 2025." ema.europa.eu. Accessed July 2026.
- European Federation of Pharmaceutical Industries and Associations. "The Pharmaceutical Industry in Figures 2025." efpia.eu. Published 2025.
- European Joint Programme on Rare Diseases. Programme Overview. ejprarediseases.org. Accessed July 2026.
- European Parliament. "Report on the Innovative Health Initiative Joint Undertaking." europarl.europa.eu. Published 2023.
- European Commission. "Horizon Europe Health Calls 2026." ec.europa.eu. Accessed July 2026.
- ClinicalTrials.gov. Database of privately and publicly funded clinical studies. clinicaltrials.gov. Accessed July 2026.
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Navigating Human Research: Mass General Brigham's IRB Guidance for Ethical Clinical Trials — Explore Mass General Brigham's comprehensive IRB guidance for ethical human subject research, crucia…